Marvin Kasmikha, DO
Family Medicine · West Bloomfield, MINPI 1134618788
Payments from drug & device makers
Across 43 payments — averaging $27.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$294
- Lilly USA, LLC$250
- Inari Medical, Inc.$131
- Abbott$130
- Dexcom, Inc.$106
- Novartis$50
- plus $223 from 12 others
What the payments were for
- Food & beverage$1,184100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 8 | $294 |
| Lilly USA, LLC | 5 | $250 |
| Inari Medical, Inc. | 1 | $131 |
| Abbott | 6 | $130 |
| Dexcom, Inc. | 6 | $106 |
| Novartis | 4 | $50 |
| Astellas Pharma US Inc | 2 | $34 |
| Bayer | 1 | $30 |
| Otsuka America Pharmaceutical, Inc. | 1 | $23 |
| Pulmonx Corporation | 1 | $20 |
| Shield Therapeutics Inc | 1 | $18 |
| Verona Pharma, Inc. | 1 | $17 |
| AstraZeneca | 1 | $16 |
| Sanofi-aventis U.S. LLC | 1 | $16 |
| Boehringer Ingelheim | 1 | $14 |
| Amgen | 1 | $13 |
| Esperion Therapeutics, Inc. | 1 | $12 |
| Seqirus USA Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,184 in reported general payments places this provider in the 70th percentile of 3,945 family medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 13 | $8,004 |
| Losartan Potassium | 29 | $514 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 14 | $500 |
| Rosuvastatin Calcium | 18 | $464 |
| Azelastine Hcl | 16 | $345 |
| Omeprazole | 11 | $303 |
| Atorvastatin Calcium | 19 | $301 |
| Metoprolol Succinate | 19 | $296 |
| Amlodipine Besylate | 18 | $266 |
| Fluticasone Propionate | 19 | $179 |
| Allopurinol | 13 | $157 |
| Levothyroxine Sodium | 12 | $127 |
| Lisinopril | 20 | $122 |
| Metformin Hcl | 11 | $45 |
Paid to pharmacies, not to this prescriber.
Other family medicine in West Bloomfield
- Derrick WilliamsonSouthfield$9.9M
- Rebecca RivardRoseville$7M
- Paul BensonBerkley$4.2M
- Michael HafranEast Lansing$2.7M
- Mitzie HewittBuckley$1.3M
- Loren ChudlerSouthfield$1.3M
- Solomon AmsterWhite Lake$981K
- Matt RosenbergJackson$559K
- Rhonda MejeurGrand Rapids$493K
- Steve LasaterSaint Johns$291K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.